Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
AbstractThe prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal metastasis. We have designed a randomized phase III trial to confirm the superiority of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1 relative to gemcitabine plus nab-PTX (GnP), which is the current standard therapy for patients with metastatic PDAC. A total of 180 patients will be accrued from 30 i...
Source: Trials - February 5, 2022 Category: Research Source Type: clinical trials
Can Four Weeks-check Cystoscopy and Urine Cytology After Primary Complete Resection of T1 Bladder Cancer Replace Repeat Biopsy?
Condition: Bladder Cancer Interventions: Procedure: Outpatient check cytoscopy; Diagnostic Test: Urine cytology Sponsor: Mansoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2021 Category: Research Source Type: clinical trials
